Specify a stock or a cryptocurrency in the search bar to get a summary
PolyPeptide Group AG
PPGNPolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V. Address: Neuhofstrasse 24, Baar, Switzerland, 6340
Analytics
WallStreet Target Price
28.33 CHFP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PPGN
Dividend Analytics PPGN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
123 %Dividend History PPGN
Stock Valuation PPGN
Financials PPGN
Results | 2019 | Dynamics |